Calcium Channel Blocker Market is segmented By Drug Class (Dihydropyridine (Amlodipine (Norvasc), Nifedipine (Procardia, Adalat), Felodipine), Nondihydropyridines (Verapamil (Calan, Isoptin), Diltiazem (Cardizem)), Benzothizepine, Phenylalkylamine, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
Calcium Channel Blocker Market is estimated to reach at a CAGR of 5.3% during the forecast period (2024-2031).
Calcium channel blockers are medications that are used to control high blood pressure, chest pain and arrhythmia. They are available through prescription and work by relaxing blood vessels and increasing the blood and oxygen supply to the heart. This reduces the workload of the heart. It can be prescribed by itself or in combination with other medications to treat high blood pressure and angina.
Calcium Channel Blocker Market Summary
|
Metrics |
Details |
|
Market CAGR |
5.3% |
|
Segments Covered |
By Drug Class, By Route of Administration, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Calcium Channel Blocker Market Dynamics
The global calcium channel blocker growth is driven by the emerging markets and huge investment in research and development are the factors responsible for the growth of this market. Moreover, the rising demand for improved healthcare infrastructure is expected to drive the market.
The increasing prevalence rate of cardiovascular diseases is expected to drive the growth in the forecast period
The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker market growth. Hypertension often referred to as elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of death and around 17.9 million people died in 2016 due to it. Calcium antagonists are known to be effective against this indication. Thus, the demand has been steadily growing for this market for better management of cardiovascular diseases. These factors are driving the growth of the market in the forecast period.
Rising assistance to people with anxiety disorders or bipolar disorder is expected to drive the market growth
A smaller population of people who do not have a heart condition could also benefit from calcium channel blockers. There is some indication they may work as mood stabilizers and be of assistance to people with anxiety disorders or bipolar disorder. The latter is particularly under investigation because some calcium channel blockers may be somewhat safer to administer to pregnant women than are most traditional mood stabilizers or antipsychotics. A few calcium channel blockers are useful in the treatment of migraine headaches, too. There are quite a few drugs that are considered calcium channel blockers and each may have its profile of side effects, risks, and benefits. Some medications that make this list include verapamil, amlodipine and diltiazem. Others are nifedipine, felodipine, and nicardipine. There are still more calcium channel blockers and others might arrive on the market if they are considered an improvement on the present supply.
Major side effects of drugs are likely to hinder the market growth
However, side effects related to calcium channel blockers such as edema, headache, rapid heart rate, and constipation are likely to hamper the overall demand for the calcium channel blocker market.
The Wall Street Journal reported that patients who took calcium channel blockers had a 60% more chance of dying of a heart attack. This is because calcium channel blocker drugs take a system that is functioning poorly and damage it even more. Many previous studies have associated calcium channel blockers with increased heart attacks, increased risk of breast cancer, increased suicide risk and increased gastrointestinal bleeding. Short-acting versions of these drugs have been previously shown to be dangerous and now long-acting versions are being shown to be possibly dangerous as well. These factors restrict market growth.
COVID-19 Impact Analysis
It has been widely observed that patients with existing cardiovascular diseases experience higher rates of complications due to COVID-19. Specifically, it has been found that patients with hypertension, diabetes and other comorbidities are at higher risk of death from the virus. During the widespread COVID-19 pandemic, there have been worries about the potential of certain blood pressure medications such as calcium channel blockers. The Centers for Disease Control and Prevention (CDC) and the European Society of Cardiology (ESC) and its council on hypertension have released position statements saying “we should not be jumping to conclusions and should not be withholding life-saving therapies from patients.” More importantly, two very recent studies attest that blood pressure drugs do not increase coronavirus risk. These factors are driving the market growth in the forecast period.
Calcium Channel Blocker Market Segment Analysis
Dihydropyridines segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Dihydropyridines target a specific type of calcium channel in the body. They cause the blood vessels to widen, lowering blood pressure. Dihydropyridine is known to exhibit more vasodilation and less negative ionotropic effect in sinoatrial and atrioventricular nodes. Amlodipine is the most common type of dihydropyridine.
Amlodipine is used with or without other medications to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Amlodipine belongs to a class of drugs known as calcium channel blockers. It works by relaxing blood vessels so blood can flow more easily. Amlodipine is also used to prevent certain types of chest pain (angina). It may help to increase your ability to exercise and decrease the frequency of angina a
Nifedipine is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your heart and blood vessels. Nifedipine is used to treat hypertension (high blood pressure) and angina (chest pain). Nifedipine may also be used for purposes not listed in this medication guide. However, Some tablet forms of nifedipine are made with a shell that is not absorbed or melted in the body. Part of the tablet shell may appear in your stool. This is a normal side effect of nifedipine and will not make the medication less effective.
Felodipine is a calcium channel blocker that is used to treat hypertension (high blood pressure) in adults. Lowering blood pressure can help lower your risk of a stroke or heart attack. Felodipine inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumours and may improve the efficacy of some antineoplastic agents.
The hospital pharmacy is expected to dominate the calcium channel blocker market during the forecast period
The hospital pharmacies held the largest share in the calcium channel blocker market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Calcium Channel Blocker Market Geographical Share
North America region holds the largest market share global Calcium Channel Blocker
North America is expected to hold a major market share in the global calcium channel blocker market due to changing lifestyles among people and the increasing prevalence rate of cardiovascular diseases. The adoption of a sedentary lifestyle has serious implications on the health of people and are known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around 60% - 85% of people, worldwide, have adopted a sedentary life. According to the Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 US adults & 1 out 5 school student meets the guideline of physical activity. Heart disease is one of the leading causes of death in the U.S., at least one person dies every 37 seconds due to cardiovascular disease, as reported by the Centre for Disease Control and Prevention.
Calcium Channel Blocker Market Competitive Landscape
The calcium channel blocker market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include ClearSynth, GlaxoSmithKline Plc., Pfizer Inc., AbMole Bioscience, Lupin Pharmaceuticals, Inc., Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, and Arbor Pharmaceuticals LLC. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the calcium channel blocker globally.
Calcium Channel Blocker Market Key Companies to Watch
Pfizer Inc.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company’s portfolio comprised of includes internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
